Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD

Roberto A. Rabinovich*, Bruce E. Miller, Karolina Wrobel, Kareshma Ranjit, Michelle C. Williams, Ellen Drost, Lisa D. Edwards, David A. Lomas, Stephen I. Rennard, Alvar Agusti, Ruth Tal-Singer, Jorgen Vestbo, Emiel F. M. Wouters, Michelle John, Edwin J. R. van Beek, John T. Murchison, Charlotte E. Bolton, William MacNee, Jeffrey T. J. Huang

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

47 Citations (Web of Science)

Abstract

Elastin degradation is a key feature of emphysema and may have a role in the pathogenesis of atherosclerosis associated with chronic obstructive pulmonary disease (COPD). Circulating desmosine is a specific biomarker of elastin degradation. We investigated the association between plasma desmosine (pDES) and emphysema severity/progression, coronary artery calcium score (CACS) and mortality. pDES was measured in 1177 COPD patients and 110 healthy control subjects from two independent cohorts. Emphysema was assessed on chest computed tomography scans. Aortic arterial stiffness was measured as the aortic-femoral pulse wave velocity. pDES was elevated in patients with cardiovascular disease (p
Original languageEnglish
Pages (from-to)1365-1373
JournalEuropean Respiratory Journal
Volume47
Issue number5
DOIs
Publication statusPublished - May 2016

Cite this